Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31059170 | 1.00 | NPSR1 (0.41) | NPSR1L3MBTL1ATMTDP1MEN1 | |
| SCHEMBL29552357 | 0.88 | ADORA1 (0.41) | NPSR1L3MBTL1ATMTDP1MEN1 | |
| SCHEMBL20394079 | 0.88 | ADORA1 (0.41) | NPSR1L3MBTL1ATMTDP1MEN1 | |
| SCHEMBL24235949 | 0.86 | ADORA1 (0.43) | NPSR1L3MBTL1ATMTDP1ADORA3 | |
| SCHEMBL536795 | 0.83 | NEK2 (0.43) | NPSR1L3MBTL1ATMTDP1ADORA3 | |
| SCHEMBL20394023 | 0.83 | NPSR1 (0.36) | NPSR1L3MBTL1ATMTDP1LMNA | |
| SCHEMBL25496358 | 0.83 | NPSR1 (0.36) | NPSR1L3MBTL1ATMTDP1LMNA | |
| SCHEMBL8715386 | 0.83 | NEK2 (0.42) | NPSR1L3MBTL1ATMTDP1ADORA3 | |
| SCHEMBL14102460 | 0.81 | L3MBTL1 (0.42) | NPSR1L3MBTL1ATMTDP1LMNA | |
| SCHEMBL8711624 | 0.81 | ADORA3 (0.40) | MEN1KMT2AADORA3ADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5688778-A | VIRICIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-11-18 | — | — | US | claimed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2020029647-A1 | METHOD FOR SYNTHESIZING NUCLEOSIDE COMPOUND AND INTERMEDIATE THEREOF | 广州市锐博生物科技有限公司 | 2020-02-13 | — | — | WO | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| US-8653254-B2 | Process for producing nucleoside | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653254-B2 | Process for producing nucleoside | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2008-10-23 | — | — | US | disclosed |
| US-7339054-B2 | Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates | MERCK & CO., INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | MERCK SHARP & DOHME CORP. | 2007-02-15 | — | — | US | disclosed |
| EP-1594882-A1 | PROCESS FOR PREPARING BRANCHED RIBONUCLEOSIDES FROM 1, 2-ANHYDRORIBOFURANOSE INTERMEDIATES | Merck & Co., Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072090-A1 | PROCESS FOR PREPARING BRANCHED RIBONUCLEOSIDES FROM 1, 2-ANHYDRORIBOFURANOSE INTERMEDIATES | MERCK & CO. INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-5821357-A | REACTING ALPHA-ANOMER ENRICHED 2,2-DIFLUOROCARBOHYDRATE WITH AT LEAST TWO MOLAR EQUIVALENTS OF METAL DERIVATIVE OF NUCLEOBASE IN LOW FREEZING INERT SOLVENT | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0577303-B1 | Stereoselective glycosylation process | LILLY CO ELI (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0577303-A1 | Stereoselective glycosylation process | ELI LILLY AND COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0467207-A2 | Purinderivate | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | NPSR1 4527/4885L3MBTL1 2273/4885ATM 3137/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | NPSR1 4527/4885L3MBTL1 2273/4885ATM 3137/4885 |
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | BMP1, BMP2, BMP4 | NPSR1 1854/4885L3MBTL1 2651/4885ATM 3050/4885 |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | NPSR1 3715/4885L3MBTL1 138/4885ATM 3845/4885 |
| US-20070037771-A1 | Reacting 2-Anhydro-3,5-di-O-(p-toluoyl)-2-C-methyl- alpha -D-ribofuranose with nucleophile such as cytosine, uracil, thymine, hypoxanthine, adenine, guanine, 7-deazaguanine, 7-deazaadenine, 7-deaza-2,6-diaminopurine, and 7-deazahypoxanthine, removing hydroxyl protecting groups | DUT, RNGTT, DPYD | NPSR1 4488/4885L3MBTL1 1430/4885ATM 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.